P
arkinson disease (PD) is clinically heterogeneous with respect to motor and nonmotor symptoms, disease course, and response to treatments. [1] [2] [3] Assessment of the disease course and prognosis is crucial to provide adequate treatment, support, and counseling. Older age at diagnosis and the postural instability and gait difficulty subtype have been consistently identified as determinants of disability, 4,5 whereas increasing age and dementia have been associated with shorter survival. 6 Autonomic dysfunction (AutD) is common in PD and includes orthostatic hypotension, constipation, bladder disturbances, and sexual dysfunction. 7 Early AutD has been consistently associated with shorter survival in multiple system atrophy [8] [9] [10] [11] [12] and has also been suggested as a determinant of survival in other synucleinopathies, such as dementia with Lewy bodies. 13 Studies that assessed the prognostic association of AutD with PD are scarce, do not generally assess AutD systematically, and lack pathologic confirmation of the diagnosis. The aim of this study was to investigate whether the time from diagnosis to development of AutD has a prognostic association with disease progression and survival in a large series of patients with PD with well-documented disease progression, follow-up until death, and postmortem confirmation of the diagnosis.
Methods

Study Design
One hundred patients with a pathologic diagnosis of PD were selected from a cohort of consecutive patients from January 1, 2006, to June 3, 2016, whose brains were donated after death to the Queen Square Brain Bank for Neurological Disorders in London, United Kingdom. Patients with the following criteria were excluded: (1) diagnosis of dementia before or within 1 year after onset of motor symptoms, 14 (2) monogenic forms of PD (eg, leucine-rich repeat kinase 2 gene [OMIM 609007], parkin, or α-synuclein), (3) coexistent neuropathologic diagnosis deemed to affect PD progression (eg, Alzheimer diseaserelated neurofibrillary tangle pathologic changes with Braak and Braak stage greater than IV or pathologic changes consistent with other concomitant neurodegenerative conditions), (4) comorbidities known to affect the autonomic nervous system (eg, diabetic ganglionopathies or neuropathies), and (5) insufficient information documenting autonomic symptoms and disease progression. The brain donor program was approved by a London Multi-Centre Research Ethics Committee, tissue was stored for research under a license from the Human Tissue Authority, and written informed consent was obtained from all donors. Data were pseudoanonymized for the study.
Clinical Assessment
All patients were regularly assessed throughout their illness by hospital specialists (neurologists or geriatricians) in the United Kingdom. A systematic review of the medical records was performed by a neurologist with expertise in movement disorders (E.D.P.-F.). Clinical features and disease progression data were collected. Date of onset of each feature was documented, and the time from diagnosis was calculated.
Autonomic dysfunction was defined by cardiovascular autonomic failure at autonomic function testing or documentation of any 2 of the following symptoms or signs persistent for longer than 6 months 11 : (1) urinary urgency, increased daytime frequency, and nocturia without hesitancy as defined by the International Continence Society 15 ; (2) constipation (<3 defecations per week, having to strain to pass stools, or regular use of laxatives); (3) symptoms of upper gastrointestinal tract dysfunction, including nausea, bloating, and early satiety; (4) symptomatic or documented orthostatic hypotension defined by a greater than 20-mm Hg decrease in systolic blood pressure or a greater than 10-mm Hg decrease in diastolic blood pressure on standing; (5) sweating abnormalities; or (6) erectile dysfunction in males. These symptoms cover the principal domains of autonomic function, and they were selected because they are well documented in medical records and are clinically relevant and easily assessed in clinical settings, where availability of neurophysiologic autonomic testing may be limited. Because some of these symptoms may be multifactorial and may be influenced by other nonneurologic factors, more than one symptom with a persistent duration was required. Six milestones were selected to define disease progression 11 : (1) frequent falls defined by more than 2 episodes per year, (2) cognitive impairment severe enough to significantly affect tasks of daily living, (3) unintelligible speech or the offering of communication aids, (4) severe dysphagia or the offering of percutaneous endoscopic gastrostomy, (5) dependence on wheelchair for mobility, and (6) placement in residential or nursing home care. These milestones have been selected because they represent the different domains of impairment of functioning in PD, including motor progression, cognitive impairment, and global disability. They are clinically relevant and, as such, are well documented in the medical records.
Other demographic data and clinical features were also recorded, including PD motor subtype (tremor predominant, akinetic rigid, or postural instability and gait difficulty), response to initial levodopa treatment measured on a semiquantitative scale (nil to mild, moderate, good, or excellent) based on the clinical impression documented by the treating physician, 11 maximum levodopa equivalent dose, 16 and clinical diagnosis at time of death. Times from diagnosis to development of AutD, each autonomic symptom, first and each disease milestone, and death were calculated.
Key Points
Question Is development of autonomic dysfunction associated with disease progression and survival in patients with Parkinson disease?
Findings In this study of 100 patients with autopsy-confirmed Parkinson disease, earlier development of autonomic dysfunction was associated with an increase in the risk of reaching a disease milestone of 14% per year and an increase in the risk of death of 8% per year.
Meaning Earlier autonomic dysfunction is associated with more rapid disease progression and shorter survival in patients with Parkinson disease.
Neuropathologic Assessment
Formalin-fixed brain tissue samples were examined using routine stains supplemented with immunohistochemical analy- 
Statistical Analysis
Summary statistics are described as number (percentage) for categorical data and mean (SD) for continuous variables. Linear regression was used to perform a preliminary analysis of potential associations among the main explanatory variables.
Time from diagnosis to AutD was considered as a dependent variable, and other relevant explanatory variables (eg, age, sex, levodopa treatment response, PD motor subtype, and Lewy pathologic type) were included as determinants in the model. To assess the association of time from PD diagnosis to AutD with the risk of developing a disease milestone or the risk of death (survival), patients were divided into 2 subgroups (eg, early vs late AutD) using the median value, and Kaplan-Meier curves were plotted. Multivariable Cox proportional hazards regression models were then used to estimate the association between the main explanatory variable and the risk of developing a disease milestone or the risk of death (survival), which were considered in turn as dependent variables. Multiple statistical tests were performed with several null hypotheses being tested (rather than one single null hypothesis with an error rate modified by every test); therefore, adjustment for multiple comparisons was considered to be inappropriate. 17, 18 Other explanatory variables included age, sex, PD motor subtype, and response to levodopa treatment. Adjusted hazard ratios (HRs) and 95% CIs were estimated, and a null hypothesis was rejected when 95% CIs did not include the null value. Visual inspection of Kaplan-Meier curves and plots of scaled Schoenfeld residuals against time were used to assess the proportional hazards assumption. Censoring was considered to be uninformative. Statistical significance was set at P < .05. Statistical analyses were performed using the STATA statistical software, version 12 (StataCorp). were clinically diagnosed with PD, whereas 12 were misdiagnosed with multiple system atrophy and 5 with progressive supranuclear palsy. 
Results
Demographic and Clinical Characteristics
Association Between AutD and Other Variables
Assessment of the association among explanatory variables (Table 2 ) revealed that patients with earlier AutD were older (regression coefficient, −0.40; 95% CI, −0.54 to −0.27; P < .001), were more likely to be male (regression coefficient, −7.13; 95% CI, −10.06 to −4.20; P < .001), had a poorer levodopa treatment response (regression coefficient, 12.19; 95% CI, 4.87 to 19.52; P = .001), had a lower maximum levodopa equivalent dose (regression coefficient, 5.56; 95% CI, 2.14 to 8.98; P = .002), and had postural instability and gait difficulty PD motor subtype (regression coefficient, −10.08; 95% CI, −15.16 to −5.00; P < .001). A clinicopathologic correlation did not reveal any significant association between AutD and limbic pathologic type (regression coefficient, 2.27; 95% CI, −9.42 to 13.96; P = .70) or diffuse neocortical pathologic subtype (regression coefficient, 2.96; 95% CI, −8.57 to 14.48; P = .61) using brainstem pathologic subtype as reference.
Association of AutD With Disease Progression
To assess progression of the disease to a certain level of disability independently of the clinical presentation, we analyzed the influence that AutD may have on the development of any (the first) disease milestone. Earlier development of AutD was associated with significantly increased risk of reaching the first disease milestone by 14% per year (HR, 0.86; 95% CI, 0.83-0.89; P < .001) (Figure and Table 3) .
We also analyzed the association of AutD with the different functioning domains by estimating the risk for each milestone (Table 3 and eFigure 2 in the Supplement). Autonomic dysfunction was associated with a higher risk of falls (HR, 0.88; 
Association of AutD With Survival
The association of time from diagnosis to AutD with survival is summarized in the Figure and Table 3 . Survival analysis was adjusted by sex, age at diagnosis, PD motor subtype, and response to levodopa treatment because they have been previously reported as survival determinants 4 and had a statistically significant association with shorter survival in the univariable analysis model in our study (see the Other Determinants of Survival subsection of the Results section). Autonomic dysfunction was associated with shorter survival, with an 8% increase of risk of death per year (HR, 0.92; 95% CI, 0.88-0.96; P < .001).
Association of Individual Autonomic Symptoms With Disease Progression and Survival
We believe that the definition of AutD reflects accurately the clinical effect of autonomic involvement in PD. To assess whether AutD was underreported by applying this definition AutD was underreported, the influence of each autonomic symptom or sign (orthostatic hypotension, urinary symptoms, constipation, upper gastrointestinal tract symptoms, sweating abnormalities, and erectile dysfunction in males) on survival and disease progression was also estimated. Earlier development of each autonomic symptom or sign was associated with a significantly higher risk of reaching a disease milestone and shorter survival (Table 3 ).
Other Determinants of Survival
Univariate models were used to study the influence of other clinical factors and demographic data on survival. In addition to earlier AutD development, factors associated with shorter survival included older age at diagnosis, male sex, postural instability and gait difficulty subtype, and poor levodopa treatment response. Only 3 of these variables (age at diagnosis, poor levodopa treatment response, and earlier development of AutD) were maintained in the multivariate analysis as independent determinants ( Table 4) .
Discussion
The main finding of the study is that earlier development of AutD or individual autonomic abnormalities (including orthostatic hypotension, urinary symptoms, upper gastrointestinal tract symptoms, constipation, sweating abnormalities, and erectile dysfunction in males) are independent determinants of more rapid disease progression and shorter survival in pa- tients with PD. The main strength of our study is that all included patients had a pathologically confirmed diagnosis. Our data highlight the significant proportion of patients with PD and AutD who are misdiagnosed as having multiple system atrophy, meaning that it is likely that many population studies have excluded this subgroup from the analysis. A few studies 19, 20 have assessed the association of the severity of autonomic symptoms with PD, but autonomic cardiovascular tests 19 or specific validated questionnaires 20 have failed to reveal any association between severity of autonomic symptoms and survival in PD. Other studies 13, 21 have assessed the influence of the presence of several symptoms of AutD on PD progression. A recent prospective cohort study 21 found that orthostatic hypotension was associated with shorter survival, although other symptoms and signs of AutD were not evaluated. In addition to orthostatic hypotension, Stubendorff and colleagues 13 27 Because the analysis was performed in the context of other motor and nonmotor symptoms, no conclusion regarding the prognostic value of these autonomic symptoms in isolation can be made. Our study agrees with the view that some symptoms might cluster together because earlier AutD was associated with postural instability and gait difficulty PD motor subtypes, which were associated with a higher risk of developing cognitive disability. In our study, AutD was an independent prognostic factor despite the association with these other features, and we propose that it should be considered as a nonmotor marker of disease for the characterization of different PD subtypes. We explored a potential association between AutD and the global distribution of α-synuclein pathologic findings in the central nervous system by using consensus criteria for the assessment of Lewy pathologic changes. These criteria provide characterization of the severity and regional involvement of Lewy pathologic changes by using a semiquantitative grading of severity in multiple areas of the brain.
14 Our results did not reveal any association between AutD and α-synuclein pathologic findings in the central nervous system; therefore, the findings did not support the hypothesis that an underlying, more aggressive neurodegenerative process is responsible for the worse prognosis in patients with AutD. However, our study did not include any specific neuropathologic assessment of central regulatory autonomic areas or peripheral postganglionic autonomic structures known to be involved in dysautonomia in PD. Therefore, we could not assess whether the neurodegenerative process has any predilection for these autonomic structures in patients with early AutD. An alternative explanation is that the increased morbidity and mortality in patients with early AutD is a consequence of the autonomic symptoms. This explanation would have important implications in clinical practice because better therapeutic control of the symptoms could potentially improve the prognosis. Medication to treat PD might also have a clinical effect on autonomic function. 28 In our study, early AutD was associated with poorer levodopa treatment response, which may be a consequence of involvement of nondopaminergic structures likely to contribute to the faster progression and disability. In addition, AutD was associated with a lower maximum levodopa equivalent dose. Although these data should be interpreted with caution, it is likely that patients with early AutD were not able to tolerate the treatment because of worsening of their autonomic symptoms. However, a poor initial response may have prevented clinicians from trying higher doses of levodopa. Our data also revealed that older age at diagnosis, male sex, PD subtype, and response to levodopa treatment were determinants of survival in univariable analysis, although identification of these determinants was not the main objective of this study. In multivariable analysis, however, only age at diagnosis, male sex, and levodopa treatment response remained significant. These features have been reported as survival determinants in PD in a previous meta-analysis. 6 
Limitations
The retrospective nature of the study and the assessment by different professionals without clear methodologic homogeneity may potentially account for some limitations in the accuracy of the recording of autonomic symptoms. The study used strict criteria and included a large group of patients with PD with detailed and regular clinical information from hospital specialists (neurologists or geriatricians) and the family physician that allowed confident documentation of the disease process. Disease milestones were well documented and accurately describe disease progression in other parkinsonian conditions. 
